Pharming Financials - Benzinga

Pharming Group

PHARNASDAQ

Trade with Public

Trade with Public

$10.77

-0.49-4.35%

À la clôture: Sep 22, 5:00 PM EST

$10.97

-0.29-2.58%

Pré-ouverture: 7:38 AM EST

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Comparer Rapport sur les stocks

Pharming Financials

Pharming (PHAR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Pharming Lowers FY2026 Sales Guidance from $405.000M-$425.000M to $375.000M-$395.000M vs $419.100M Est

Pharming (NASDAQ:PHAR) lowers FY2026 sales outlook from $405.000 million-$425.000 million to $375.000 million-$395.000 million vs $419.100 million estimate.

Benzinga Newsdesk

PRO
Pharming Q2 EPS $0.02, Inline, Sales $90.200M Miss $100.625M Estimate

Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 66.67 percent decrease over earnings of $0.06 per share from the same period last year. The

Benzinga Newsdesk

PRO
Pharming Affirms FY2026 Sales Guidance of $405.000M-$425.000M vs $421.375M Est

Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $405.000 million-$425.000 million to $405.000 million-$425.000 million vs $421.375 million estimate.

Benzinga Newsdesk

PRO
Pharming Projects FY2026 Total Revenues Of $405M-$425M With 8%-13% Growth Amid Pipeline Investments And Cost Reductions

For 2026, the Company anticipates: Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected.Total operating expenses between US$330 million and US$335 million

Benzinga Newsdesk

PRO
Pharming Q1 EPS $(0.07) Misses $0.01 Estimate, Sales $72.400M Miss $93.750M Estimate

Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.01 by 800 percent. This is a 68.18 percent increase over losses of $(0.22) per share from the same

Benzinga Newsdesk

Earnings Scheduled For March 12, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved